HDAC6 and cystic kidney disease: Histone deacetylase 6 (HDAC6) inhibitors such as ACY-1215, Tubacin, Trichostatin A (TSA), Valproic acid (VPA) and Nicotinamide have shown to ameliorate cystic kidney disease in in vitro and in vivo models, however, some of these drugs have uncertain safety profiles and are yet to be tested in clinical trials.